Page last updated: 2024-08-23

rafoxanide and Multiple Myeloma

rafoxanide has been researched along with Multiple Myeloma in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Bu, W; Chang, S; Chen, G; Gao, L; Kong, Y; Lan, X; Li, B; Shi, J; Sun, X; Wang, Y; Wu, H; Wu, X; Xiao, W; Xie, B; Xie, Y; Xu, Z; Yu, D; Zhu, W	1

Other Studies

1 other study(ies) available for rafoxanide and Multiple Myeloma

Article	Year
Rafoxanide, an organohalogen drug, triggers apoptosis and cell cycle arrest in multiple myeloma by enhancing DNA damage responses and suppressing the p38 MAPK pathway. Cancer letters, 2019, 03-01, Volume: 444 Topics: Animals; Antinematodal Agents; Apoptosis; Cell Cycle Checkpoints; Cell Movement; Cell Proliferation; DNA Damage; Female; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Multiple Myeloma; p38 Mitogen-Activated Protein Kinases; Rafoxanide; Tumor Cells, Cultured; Tumor Microenvironment; Xenograft Model Antitumor Assays	2019

Article

Year

Rafoxanide, an organohalogen drug, triggers apoptosis and cell cycle arrest in multiple myeloma by enhancing DNA damage responses and suppressing the p38 MAPK pathway.

Cancer letters, 2019, 03-01, Volume: 444

Topics: Animals; Antinematodal Agents; Apoptosis; Cell Cycle Checkpoints; Cell Movement; Cell Proliferation; DNA Damage; Female; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Multiple Myeloma; p38 Mitogen-Activated Protein Kinases; Rafoxanide; Tumor Cells, Cultured; Tumor Microenvironment; Xenograft Model Antitumor Assays

2019